Allergy Therapeutics Sees End FDA Hold If Cervarix Approved
Wall Street Journal An approval would mark a positive change in the environment for Allergy's US plans for its Pollinex Quattro hayfever vaccine, Allergy said. Like Cervarix, it uses the vaccine adjuvant MPL to boost its effectiveness, but the FDA halted a major trial of … |